- Home
- ACM vs EXAS Comparison
ACM vs EXAS Comparison
Compare ACM & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACM | EXAS |
|---|---|---|
| Founded | 1980 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6B | 19.3B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACM | EXAS |
|---|---|---|
| Price | $98.94 | $101.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 20 |
| Target Price | ★ $134.00 | $77.94 |
| AVG Volume (30 Days) | 1.4M | ★ 3.7M |
| Earning Date | 02-02-2026 | 02-18-2026 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | ★ 42.91 | N/A |
| EPS | ★ 4.22 | N/A |
| Revenue | ★ $16,139,622,000.00 | $3,082,033,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | $3.13 | $13.51 |
| P/E Ratio | $22.86 | ★ N/A |
| Revenue Growth | 0.21 | ★ 14.47 |
| 52 Week Low | $85.00 | $38.81 |
| 52 Week High | $135.52 | $102.66 |
Technical Indicators
Market Signals| Indicator | ACM | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 39.85 | 80.65 |
| Support Level | $95.00 | $101.55 |
| Resistance Level | $97.91 | $102.05 |
| Average True Range (ATR) | 1.68 | 0.38 |
| MACD | 0.97 | -1.16 |
| Stochastic Oscillator | 87.05 | 31.17 |
Price Performance
Historical ComparisonAbout ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.